TriSalus Life Sciences, Inc. - Common Stock (TLSI)

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) investors concerning the Company’s possible violations of federal securities laws.

Shareholders who held TriSalus Life Sciences Inc. (TLSI) stock lost money after the company cut its full-year 2026 revenue guidance to $54 million-$57 million, down from the $60 million-$62 million range reaffirmed approximately two months earlier on March 5, 2026. Those who purchased TLSI shares and suffered losses are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The Law Offices of Frank R. Cruz announces an investigation of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI) on behalf of investors concerning the Company’s possible violations of federal securities laws.

TriSalus (TLSI) Q1 2026 Earnings Transcript

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device. President and Chief Executive Officer M

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended March 31, 2026, and provided an operational update.

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of the largest real-world evidence study to date evaluating the clinical and economic impact of Pressure-Enabled Drug Delivery (PEDD®) technology used in trans-arterial chemoembolization (TACE) and radioembolization (TARE) procedures.

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study designed to evaluate its novel Pressure-Enabled Drug Delivery™ (PEDD™) approach in patients with primary or metastatic liver tumors.

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended March 31, 2026. A press release detailing the results will be issued prior to the call.

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada.

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Director, a role he has held since January 2025. In his new capacity, he will lead the Company’s medical strategy and provide clinical leadership across development, evidence generation and broader strategic initiatives.

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of preclinical research evaluating Pressure-Enabled Drug Delivery™ (PEDD™) of nelitolimod in liver tumor models in Frontiers in Oncology.

TriSalus (TLSI) Q4 2025 Earnings Call Transcript

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter and year ended December 31, 2025, and provides an operational update.

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday, March 5, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended December 31, 2025. A press release detailing the results will be issued prior to the call.

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced it has priced its previously announced underwritten public offering of 9,756,100 shares of its common stock at a public offering price of $4.10 per share. All of the shares in the offering are being sold by TriSalus. In addition, TriSalus has granted the underwriter a 30-day option to purchase up to 1,463,415 shares of common stock, which equals 15% of the total number of shares of common stock sold in the offering, at the public offering price, less underwriting discounts and commissions. The gross proceeds to TriSalus from the offering are expected to be approximately $40.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by TriSalus. The offering is expected to close on or about February 23, 2026, subject to the satisfaction of customary closing conditions.